Company intelligence / Profile preview
Hummingbird Bioscience
Singapore, Singaporehummingbirdbioscience.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 1
01
Overview
Hummingbird Bioscience has advanced two main clinical-stage assets—HMBD‑001, a humanized anti-HER3 monoclonal antibody, and HMBD‑002, a humanized anti-VISTA IgG4 monoclonal antibody—both in Phase I trials as of early/mid‑2024. The company has also outlicensed its next-generation HER3-targeted ADC program HMBD‑501 to Endeavor BioMedicines with an IND planned for the first half of 2024. Additionally, it licensed its multipayload ADC platform to Callio Therapeutics in March 2025.[5][8] No pivotal efficacy data have been publicly disclosed yet.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)[1][5][6]
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Synaffix — licensing agreement for proprietary ADC technologies GlycoConnect®, HydraSpace®, toxSYN® linkers/payloads[9]Endeavor BioMedicines — exclusive worldwide license for HMBD–501 program[5]Callio Therapeutics — exclusive worldwide license agreement covering multipayload ADC platform and pipeline assets in oncology [8]
Beyond the preview
Go deeper on Hummingbird Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hummingbird Bioscience.